ObsEva's preterm labor candidate well tolerated in Phase I

ObsEva S.A. (NASDAQ:OBSV) reported data from a Phase I trial in 36 healthy postmenopausal women showing that single and multiple ascending oral doses of preterm labor candidate OBE022 were well tolerated with no serious adverse events reported. Data were presented at the Society for Reproductive Investigation meeting in San Diego. The double-blind, placebo-controlled, U.K. trial evaluated safety and pharmacokinetics...